2026-03-20 21:16:45
REGENXBIO Inc. Enters Settlement Agreement with GlaxoSmithKline for $10 Million
Expected Stock impact: Slightly Negative
On March 18, 2026, REGENXBIO Inc. announced that it has entered into a Settlement and Release Agreement with GlaxoSmithKline LLC (GSK) to resolve a dispute related to the License Agreement dated March 6, 2009. The settlement comes after non-binding mediation regarding the amount of sublicense fees that REGENXBIO owed to GSK under the GSK-REGENXBIO Sublicense. As part of the agreement, REGENXBIO will pay GSK $10 million within three business days for alleged underpayment of sublicense fees on amounts received from sublicensees, including royalties. The Settlement Agreement includes mutual releases of all past claims arising out of or related to the GSK-REGENXBIO Sublicense, as well as certain specified types of future claims. REGENXBIO will continue to pay GSK amounts received from sublicensees according to its existing allocation methodology. This settlement is expected to have a small negative impact on REGENXBIO's liquidity due to the immediate cash outflow required, although it resolves a potentially larger dispute that could have had more significant financial implications if left unresolved. The company plans to disclose further details in its upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2026.
